Laboratory Study| Volume 16, ISSUE 12, P1615-1618, December 2009

Download started.


Antigen p57/Kip2 as a potential negative regulator of human astrocytoma growth


      This study was performed to determine the relationship between p57/Kip2 and the growth of human astrocytomas. Immunohistochemical staining for p57/Kip2, p53, p16, and Ki67 antigen was performed on paraffin-embedded tissue specimens obtained from 36 patients with astrocytoma. Expression of p57/Kip2, p53, p16, and Ki67 antigen was generally increased in association with the astrocytoma tumor grade. Expression of p16 was higher in patients whose tumors express p57/Kip2 in greater than 10% of tumor cells (p < 0.05). Expression of p53 also tended to be higher, but not to a statistically significant extent, in patients whose tumors express p57/Kip2 in greater than 10% of tumor cells. These findings suggest that p57/Kip2 inhibits the growth of human astrocytomas, and may function in parallel with p16 and p53. However, p57/Kip2 is, by itself, insufficient to arrest the cellular proliferation of human astrocytomas.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Clinical Neuroscience
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Tsugu A.
        • Sakai K.
        • Dirks P.B.
        • et al.
        Expression p57/Kip2 potently blocks the growth of human astrocytomas and induces cell senescence.
        Am J Pathol. 2000; 157: 919-932
        • Sakai K.
        • Peraud A.
        • Mainprize T.
        • et al.
        Inducible expression of p57/KIP2 inhibits glioma cell motility and invasion.
        J Neurooncol. 2004; 68: 217-223
        • Bansal K.
        • Liang M.L.
        • Rutka J.T.
        Molecular biology of human astrocytomas.
        Technol Cancer Res Treat. 2006; 5: 185-194
        • Dirks P.B.
        • Hubbard S.L.
        • Murakami M.
        • et al.
        Cyclin and cyclin-dependent kinase expression in human astrocytoma cell lines.
        J Neuropathol Exp Neurol. 1997; 56: 291-300
        • Dirks P.B.
        • Rutka J.T.
        Current concepts in neuro-oncology: the cell cycle-a review.
        Neurosurgery. 1997; 40: 1000-1015
        • Lee M.H.
        • Reynisdóttir I.
        • Massagué J.
        Cloning of p57/KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution.
        Genes Dev. 1995; 9: 639-649
        • Luo Y.
        • Hurwitz J.
        • Massagué J.
        Cell-cycle inhibition by independent CDK and PCNA binding domains in p21/Cip1.
        Nature. 1995; 375: 159-161
        • Vaccarello G.
        • Figliola R.
        • Cramerotti S.
        • et al.
        p57KIP2 is induced by MyoD through a p73-dependent pathway.
        J Mol Biol. 2006; 356: 578-588
        • Cam H.
        • Griesmann H.
        • Beitzinger M.
        • et al.
        p53 Family members in myogenic differentiation and rhabdomyosarcoma development.
        Cancer Cell. 2006; 10: 281-293
        • Fan G.K.
        • Xu F.
        • Yang B.
        • et al.
        p57(KIP2) expression is related to carcinogenesis and tumor progression in laryngeal tissues.
        Acta Otolaryngol. 2006; 126: 301-305
        • Georgia S.
        • Soliz R.
        • Li M.
        • et al.
        p57 and Hes1 coordinate cell cycle exit with self-renewal of pancreatic progenitors.
        Dev Biol. 2006; 298: 22-31
        • Go J.H.
        Expressions of the CIP/KIP family of CDK inhibitor proteins in primary intestinal large B-cell lymphomas: correlation with clinical outcomes.
        Pathol Res Pract. 2002; 198: 741-746
        • Hayslip J.
        • Montero A.
        Tumor suppressor gene methylation in follicular lymphoma: a comprehensive review.
        Mol Cancer. 2006; 6: 5-44
        • Ito Y.
        • Takeda T.
        • Wakasa K.
        • et al.
        Expression of p57/Kip2 protein in pancreatic adenocarcinoma.
        Pancreas. 2001; 23: 246-250
        • Ito Y.
        • Takeda T.
        • Wakasa K.
        • et al.
        Expression of p57/Kip2 protein in hepatocellular carcinoma.
        Oncology. 2001; 61: 221-225
        • Ito Y.
        • Yoshida H.
        • Nakano K.
        • et al.
        Expression of p57/Kip2 protein in normal and neoplastic thyroid tissue.
        Int J Mol Med. 2002; 9: 373-376
        • Ito Y.
        • Takeda T.
        • Sasaki Y.
        • et al.
        Expression of p57/Kip2 protein in extrahepatic bile duct carcinoma and intrahepatic cholangiocellular carcinoma.
        Liver. 2002; 22: 145-149
        • Ito Y.
        • Yoshida H.
        • Matsuzuka F.
        • et al.
        Expression of the components of the Cip/Kip family in malignant lymphoma of the thyroid.
        Pathobiology. 2004; 71: 164-170
        • Matsumoto M.
        • Furihata M.
        • Ohtsuki Y.
        • et al.
        Immunohistochemical characterization of p57/Kip2 expression in human esophageal squamous cell carcinoma.
        Anticancer Res. 2000; 20: 1947-1952
        • Matsuoka S.
        • Edwards M.C.
        • Bai C.
        • et al.
        p57/KIP2, a structurally distinct member of the p21/CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene.
        Genes Dev. 1995; 9: 650-662
        • Pateras I.S.
        • Apostolopoulou K.
        • Koutsami M.
        • et al.
        Downregulation of the KIP family members p27(KIP1) and p57(KIP2) by SKP2 and the role of methylation in p57(KIP2) inactivation in nonsmall cell lung cancer.
        Int J Cancer. 2006; 119: 2546-2556
        • Popiolec D.A.
        • Yee H.
        • Mittal K.
        • et al.
        Multiplex short tandem repeat DNA analysis confirms the accuracy of p57(KIP2) immunostaining in the diagnosis of complete hydatidiform mole.
        Hum Pathol. 2006; 37: 1426-1434
        • Rothschild G.
        • Zhao X.
        • Iavarone A.
        • et al.
        E proteins and Id2 converge on p57/Kip2 to regulate cell cycle in neural cells.
        Mol Cell Biol. 2006; 26: 4351-4361
        • Stampfer M.R.
        • Garbe J.
        • Nijjar T.
        • et al.
        Loss of p53 function accelerates acquisition of telomerase activity in indefinite lifespan human mammary epithelial cell lines.
        Oncogene. 2003; 22: 5238-5251